---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-056130"
form_type: "8-K"
ticker: "IRWD"
cik: "0001446847"
company_name: "IRONWOOD PHARMACEUTICALS INC"
filed_at: "2022-05-05T23:59:59+00:00"
generated_at: "2026-06-25T23:33:54.068034+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Ironwood Q1 2022: LINZESS Rx demand +11%; net sales $232M; GAAP net income $39M

## Summary
- LINZESS U.S. net sales $232M (+8% YoY); prescription demand growth +11% YoY.
- Total revenue $98M; GAAP net income $39M ($0.21 diluted EPS).
- Adjusted EBITDA $58M, up from $46M; cash and equivalents $593M.
- Full-year 2022 financial guidance reaffirmed; LINZESS exceeded $1B in 2021.
- CEO cites progress in clinical trials and plans to in-license or acquire GI assets.

## SEC filing metadata
- accession: 0001104659-22-056130
- form_type: 8-K
- ticker: IRWD
- cik: 0001446847
- company_name: IRONWOOD PHARMACEUTICALS INC
- filed_at: 2022-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1446847/000110465922056130/0001104659-22-056130-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1446847/000110465922056130/tm2214395d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-056130
- JSON: https://secwatch.observer/filing/0001104659-22-056130.json
- Plain text: https://secwatch.observer/filing/0001104659-22-056130.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.